Ivermectin is an off-patent (generic), inexpensive medication which is considered by some to be an effective treatment for COVID-19 as suggested by numerous, constantly updated studies compiled online and by peer-reviewed studies worldwide. The Chairman of the Japanese medical association announced in late August 2021 that physicians should use ivermectin to treat Covid-19, but it continues to be suppressed by liberals in the United States. "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19," according to a study published in a journal posted by the NIH's National Library of Medicine.
Ivermectin has been described as:
|“|| a cheap, safe drug designed to treat parasites that had almost no known side effects ....
“We kind of thought, well, there’s no negatives to taking this,” said [a COVID patient]. “It’s not going to have any really bad side effects. If it could help, why not?” Within 24 hours, her fever was gone. After two days, Coutts felt completely herself again.
The NIH wrote:
|“||Ivermectin is a drug that many people will never have heard of. Yet thousands of villagers of all ages in communities scattered throughout the remotest parts of Africa and Latin America know its name, and some experts regard it as one of the greatest health interventions of the past 50 years. Ivermectin was brought to the commercial market place for multi-purpose use in animal health in 1981. Six years later it was registered for human use. This remarkable compound has improved the lives and productivity of billions of humans, livestock and pets around the globe, and promises to help consign to the history books two devastating and disfiguring diseases that have plagued people throughout the tropics for generations–while new uses for it are continually being found.||”|
Researchers at Queen Mary, University of London, published a paper in August 2021 which concluded that:
|“||from the Bayesian meta-analysis for patients with severe Covid-19, the mean probability of death without ivermectin treatment is 22.9%, whilst with the application of ivermectin treatment it is 11.7%||”|
In the summer of 2021, a peer-reviewed journal found significant benefits from ivermectin:
|“||Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.||”|
A majority of studies show that ivermectin has been effective for early treatment and prophylactic use.
The FDA generally opposes, disparages, and downplays the benefits of early treatment for COVID-19.
The FDA has publicized isolated reports of patients who have required medical support and been hospitalized after self-medicating with ivermectin intended for horses. Ivermectin has been approved as safe by the FDA and thus can be used when prescribed "off-label" for new uses, such as treating COVID-19.
Ivermectin tablets are approved at specific doses for some parasitic worms, and there are topical (on the skin) formulations for head lice and skin conditions like rosacea. Ivermectin is not an anti-viral (a drug for treating viruses). Taking large doses of this drug is dangerous and can cause serious harm. Ivermectin preparations for animals are very different from those approved for humans.
Randomized Trial Negative Results
Double-blind, randomized trial that included 476 patients and conducted at a single site in Cali, Colombia, did not support the use of ivermectin for treatment of mild COVID-19. Larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes. 
University of Oxford Study
The University of Oxford in the UK has added ivermectin to the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE) study for the treatment of Covid-19. In small pilot studies, early use of ivermectin was able to lower viral load and the duration of symptoms in some mild Covid-19 patients.